Should I Buy STOK? STOK 2026 Analysis

Should You Buy Stoke Therapeutics Inc (STOK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

31.070

1 Day change

5.68%

52 Week Range

38.690

Analysis Updated At

2026/01/26

Stoke Therapeutics Inc (STOK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including promising clinical data, significant analyst upgrades, and a growing addressable market. Despite some technical neutrality, the long-term growth potential outweighs short-term fluctuations.

Technical Analysis

The MACD is below zero and negatively contracting, indicating a bearish momentum. RSI is neutral at 40.669, and moving averages are converging, showing no clear trend. Key support is at 26.347, and resistance is at 33.319. The stock has a 60% chance to gain 9.98% in the next month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio indicates bullish sentiment, while the high Option Volume Put-Call Ratio suggests short-term bearish sentiment due to higher put activity.

Technical Summary

Sell

Buy

Positive Catalysts

Promising clinical data for zorevunersen showing 82% seizure reduction and cognitive gains.
Analyst upgrades with higher price targets (e.g., Canaccord raised to $36, H.C. Wainwright to $50).
Revenue growth of 117.25% YoY in Q3 2025.

Neutral/Negative Catalysts

Net income is still negative at -$38.35M, though improving.
No recent news or significant insider/hedge fund activity.
Technical indicators are neutral, showing no immediate bullish momentum.

Financial Performance

In Q3 2025, revenue increased by 117.25% YoY to $10.63M. Net income improved by 45.09% YoY to -$38.35M. EPS rose by 38.30% YoY to -0.65. Gross margin remains strong at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are bullish on STOK. Recent upgrades include Canaccord raising the price target to $36 and H.C. Wainwright to $50, citing transformative clinical data and an expanded addressable market. The stock has a high probability of success in its Phase 3 EMPEROR study.

9 Analyst Rating

Wall Street analysts forecast STOK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STOK is 35.75 USD with a low forecast of 25 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 29.400

Low

Averages

35.75

High

Current: 29.400

Low

Averages

35.75

High

Canaccord

Buy

maintain

$28 -> $36

AI Analysis

2026-01-05

Reason

Canaccord

Price Target

$28 -> $36

AI Analysis

2026-01-05

maintain

Buy

Reason

Canaccord raised the firm's price target on Stoke Therapeutics to $36 from $28 and keeps a Buy rating on the shares. The firm updated its model following the release of promising zorevunersen data on its potential to modify progression of Dravet syndrome vs. simply manage symptoms such as seizures a la current standard-of-care. Canaccord noted the company expected to meet with the FDA in December 2025 and they are eagerly awaiting the outcome of the FDA interactions.

H.C. Wainwright

Buy

maintain

$35 -> $50

2025-12-15

Reason

H.C. Wainwright

Price Target

$35 -> $50

2025-12-15

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Stoke Therapeutics to $50 from $35 and keeps a Buy rating on the shares. The firm says zorevunersen's "clinically transformative" 82% seizure reduction and "significant" cognitive gains substantially de-risk the Phase 3 EMPEROR study "which is powered for far more modest improvements." The analyst received "strong" validation from key opinion leaders supporting its use in severe patients despite safety signals. The new data expande the addressable market to "Atypical Dravet," the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for STOK

Unlock Now

STOK Should I Buy

STOK Should I Buy

Should You Buy Stoke Therapeutics Inc (STOK) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch